封面
市場調查報告書
商品編碼
1473917

全球生物模擬市場規模、佔有率、成長分析、依應用(藥物開發、藥物發現)、最終用戶(製藥和生物技術公司、學術機構和研究實驗室)- 2024-2031 年產業預測

Global Biosimulation Market Size, Share, Growth Analysis, By Application(drug development, drug discovery), By End user(pharmaceutical and biotechnology companies, academic institutes and research laboratories) - Industry Forecast 2024-2031

出版日期: | 出版商: SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

2022年全球生物模擬市場規模為28.1億美元,預計將從2023年的32.8億美元成長到2031年的114.6億美元,在預測期間(2024-2031年)複合年成長率為16.90%。

生物模擬利用電腦程式模擬生物過程,透過預測未來的實驗結果,在藥物發現和開發中找到了多種應用。考慮到後期藥物開發涉及的巨大成本和資源,它在預測藥物分子的功效和潛在失敗方面的作用至關重要。特別值得注意的是,在 COVID-19 大流行期間,其需求激增,其在疫苗開發中的關鍵作用證明了這一點。例如,領先的生物模擬技術公司 Certara 迅速調整其服務以協助疫苗開發商,強調了對生物模擬工具的高度依賴來應對藥物開發課題,從而推動市場成長。

目錄

執行摘要

  • 市場概況
  • 命運之輪

研究方法論

  • 資訊採購
  • 二手和主要資料來源
  • 市場規模估計
  • 市場假設與限制

母公司市場分析

  • 市場概況
  • 市場規模
  • 市場動態
    • 促進要素
    • 機會
    • 限制
    • 課題

主要市場洞察

  • 技術分析
  • 定價分析
  • 供應鏈分析
  • 價值鏈分析
  • 市場生態系統
  • 智慧財產權分析
  • 貿易分析
  • 啟動分析
  • 原料分析
  • 創新矩陣
  • 管道產品分析
  • 總體經濟指標
  • 頂級投資分析
  • 成功的關鍵因素
  • 競爭程度

市場動態與展望

  • 市場動態
    • 促進要素
    • 機會
    • 限制
    • 課題
  • 監管環境
  • 波特分析
  • 對未來顛覆的特別見解

依應用分類的全球生物模擬市場

  • 市場概況
  • 藥物開發
  • 藥物發現
  • 其他

依最終用戶分類的全球生物模擬市場

  • 市場概況
  • 製藥和生物技術公司
  • 學術機構與研究實驗室
  • 合約研究組織
  • 和別的

依地區分類的全球生物模擬市場規模

  • 市場概況
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 西班牙
    • 法國
    • 英國
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 拉丁美洲
    • 巴西
    • 拉丁美洲其他地區
  • 中東和非洲 (MEA)
    • 海灣合作理事會國家
    • 南非
    • MEA 的其餘部分

競爭格局

  • 前 5 名企業比較
  • 2023 年關鍵參與者的市場定位
  • 主要市場參與者所採取的策略
  • 最佳制勝策略
  • 近期市集活動
  • 主要公司市佔率 (%), 2023

主要公司簡介

  • Certara
  • Dassault Systemes SE
  • Simulations Plus Inc.
  • Schrodinger Inc.
  • Physiomics Plc
  • Advanced Chemistry Development Inc.
  • In silico biosciences Inc.
  • Genedata AG
  • Evidera Inc.
  • Leadscope Inc.
  • Insilico Biotechnology AG
  • Rhenovia Pharma SAS
  • Entelos Inc.
  • Biocomputing Platforms Ltd.
  • Rosa & Co. LLC
  • Genedata AG
  • OpenEye Scientific Software Inc.
  • Nexelis
  • Compugen Ltd.
  • Chemical Computing Group ULC
簡介目錄
Product Code: SQMIG35I2104

Global Biosimulation Market size was valued at USD 2.81 billion in 2022 and is poised to grow from USD 3.28 billion in 2023 to USD 11.46 billion by 2031, growing at a CAGR of 16.90% during the forecast period (2024-2031).

Biosimulation, utilizing computer programs to simulate biological processes, finds diverse applications in drug discovery and development by enabling prediction of future outcomes of experiments. Its role in foreseeing the efficacy and potential failures of drug molecules is crucial, given the immense costs and resources involved in late-stage drug development. Particularly notable is its surge in demand during the COVID-19 pandemic, as evidenced by its pivotal role in vaccine development. For instance, Certara, a leading biosimulation technology company, swiftly adapted its services to assist vaccine developers, underscoring the heightened reliance on biosimulation tools to navigate drug development challenges, thereby fueling market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Biosimulation Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Biosimulation Market Segmental Analysis

The global biosimulation market is divided into three sections: offering type, application, and end user. The market is classified into two types of offerings: software and services. The software segment is divided into the following categories: PK/PD modelling and simulation, PBPK modelling and simulation, trial simulators, molecular modelling, and others. The Biosimulation Market is classified into three applications: drug discovery, drug development, and others. End users in the Biosimulation Market include contract research organisations, pharmaceutical and biotechnology companies, research institutes, regulatory institutes, and others. By region, the Biosimulation Market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Biosimulation Market

The global biosimilars market is witnessing growth propelled by multiple factors. These include the mounting imperative to reduce healthcare expenditures, heightened interest in cost-effective biosimilars, escalating incidence rates of diverse diseases, expanding array of off-patent drugs, promising outcomes from ongoing clinical trials, and surging demand for biosimilars across therapeutic domains like rheumatoid arthritis and blood disorders.

Restraints in the Global Biosimulation Market

The utilization of biosimulation technologies in drug discovery and development lacks standardization, employing various models and techniques to register and process diverse biological events. Due to the heightened complexity, storing, modifying, and sharing data and models pose challenges for researchers. Standardization is essential to ensure the production of dependable and efficient outcomes. However, the absence of standards from regulatory authorities stands as a major impediment to the expansion of the biosimulation industry.

Market Trends of the Global Biosimulation Market

A primary factor propelling market expansion is the escalating occurrence of drug relapse incidents linked to drug resistance in ailments like cancer, tuberculosis, and bacterial infections. Furthermore, the market is influenced by heightened governmental funding aimed at fostering the uptake of these remedies. Moreover, the biosimulation sector gains from augmented healthcare expenditure, enhancements in healthcare infrastructure, and a growing demand for comprehensive care provision.

Table of Contents

Executive Summary

  • Market Overview
  • Wheel of Fortune

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Parent Market Analysis

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges

Key Market Insights

  • Technology Analysis
  • Pricing Analysis
  • Supply Chain Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • IP Analysis
  • Trade Analysis
  • Startup Analysis
  • Raw Material Analysis
  • Innovation Matrix
  • Pipeline Product Analysis
  • Macroeconomic Indicators
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Regulatory Landscape
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers
  • Skyquest Special Insights on Future Disruptions
    • Political Impact
    • Economic Impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Global Biosimulation Market by Application

  • Market Overview
  • drug development
  • drug discovery
  • and others

Global Biosimulation Market by End user

  • Market Overview
  • pharmaceutical and biotechnology companies
  • academic institutes and research laboratories
  • contract research organisations
  • and others

Global Biosimulation Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2023
  • Strategies Adopted by Key Market Players
  • Top Winning Strategies
    • By Development
    • By Company
    • By Year
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2023

Key Company Profiles

  • Certara
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Dassault Systemes SE
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Simulations Plus Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Schrodinger Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Physiomics Plc
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Advanced Chemistry Development Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • In silico biosciences Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Genedata AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Evidera Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Leadscope Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Insilico Biotechnology AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Rhenovia Pharma SAS
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Entelos Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Biocomputing Platforms Ltd.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Rosa & Co. LLC
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Genedata AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • OpenEye Scientific Software Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Nexelis
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Compugen Ltd.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Chemical Computing Group ULC
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments